Cingulate_Logo_400x400_twitter.jpg
Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
13 nov. 2023 16h15 HE | Cingulate Inc.
Phase 3 Adult Efficacy and Safety Trial Data Presented at Psych Congress Cingulate Closed a $4M Public Offering $5.8M of Debt Converted into CING Equity KANSAS CITY, Kan., Nov. 13, 2023 (GLOBE...
Lifeist.png
Lifeist's Mikra Completes Formulation of Innovative Mental Health Product for Anxiety 
02 nov. 2023 07h00 HE | Lifeist Wellness Inc.
Mikra introduces Serenity, a new innovative product based on an extract of lavender oil aimed at supporting mental health
Cingulate_Logo_400x400_twitter.jpg
Cingulate to Host CNS Key Opinion Leader Panel in New York City
17 oct. 2023 14h22 HE | Cingulate Inc.
KANSAS CITY, Kan., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
MDbio_Logo.png
Groundbreaking Study Finds Natural Formulation by MDbio – The Doctors BrandTM Significantly Improves Sleep, Anxiety, Stress, and Overall Well-being
03 oct. 2023 09h00 HE | MDbio
Los Angeles, CA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- In a momentous large-scale clinical trial, a MDSleep formulation by MDbio – The Doctors BrandTM was proven to significantly improve sleep compared...
Lifeist.png
Lifeist's Mikra Introduces Innovative New Mental Health Product and Provides Corporate Update
26 sept. 2023 07h00 HE | Lifeist Wellness Inc.
TORONTO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Inc. to Present at the LD Micro Main Event XVI
21 sept. 2023 13h30 HE | Cingulate Inc.
KANSAS CITY, Kan., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
logo.png
Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
20 sept. 2023 08h28 HE | Silo Pharma, Inc.
Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
14 août 2023 16h15 HE | Cingulate Inc.
Werth Family Investment Associates Provides Additional Capital InvestmentPhase 3 Adult Efficacy and Safety Trial of CTx-1301 Data ReleasedCTx-1301 Phase 3 Pediatric and Adolescent Studies Underway ...
ihl_logo.png
Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
28 juil. 2023 07h30 HE | Incannex Healthcare
MELBOURNE, Australia, July 28, 2023 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is...
MDbio_Logo.png
MDbio – The Doctors BrandTM Publishes New Article About Artificial Intelligence in Healthcare
24 juil. 2023 09h00 HE | MDbio Wellness
Beverly Hills, California, July 24, 2023 (GLOBE NEWSWIRE) --  MDbio – The Doctors BrandTM published a new article about artificial intelligence in healthcare and what the future of this industry...